Summit Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Summit Therapeutics generated cash of -$76,760,000, which is less than the previous year. Cash used in financing activities reached the amount of $86,513,000 last year. Net change in cash is therefore -$577,182,000.
Cash Flow
| 2010 | -2.64M | -115.02K | 8.13M |
|---|---|---|---|
| 2011 | -4.33M | -170.91K | 25.32K |
| 2012 | -3.80M | -172.73K | 2.13M |
| 2016 | -24.47M | -51.27K | 22.13M |
| 2018 | -20.79M | -7.41M | 19.68M |
| 2019 | -15.56M | -265.32K | 37.46M |
| 2020 | -48.11M | -421K | 50.55M |
| 2021 | -72.58M | -306K | 77.91M |
| 2022 | -41.58M | -624K | 620.24M |
| 2023 | -76.76M | -587.77M | 86.51M |
SMMT Cash Flow Statement (2010 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 648.60M | 71.79M | 66.41M | 63.84M | 22.26M | 39.72M | 16.04M | 5.10M | 9.62M | 4.34M |
Operating activities | ||||||||||
Net income | -614.92M | -78.78M | -88.60M | -52.69M | -23.88M | -15.41M | -28.69M | -4.23M | -9.38M | -9.20M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.05M | 2.51M | 2.45M | 2.00M | 1.39M | 348.20K | 68.36K | 295.21K | 710.54K | 3.78M |
Stock-based compensation expense | 14.10M | 9.88M | 12.80M | 1.76M | 542.04K | 2.27M | 1.65M | 97.35K | 117.10K | -28.75K |
| Deferred income tax benefit | 14.10M | 9.88M | 12.80M | 1.76M | 542.04K | 2.27M | 1.65M | 97.35K | 117.10K | -28.75K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 4.52M | 975K | -1.13M | 212K | 4.63M | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 3.59M | -6.60M | -1 | 0 | 0 | 0 | 0 | 289.16K |
Accounts payable | 2.26M | -4.13M | -1.71M | 1.64M | -997.71K | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -76.76M | -41.58M | -72.58M | -48.11M | -15.56M | -20.79M | -24.47M | -3.80M | -4.33M | -2.64M |
Investing activities | ||||||||||
Purchases Of Investments | -321.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -128K | -624K | -306K | -421K | -265.32K | -678.00K | -93.99K | -190.00K | -193.06K | -140.58K |
Acquisitions Net | 0 | 0 | 0 | 0 | -99.19K | -6.75M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -587.77M | -624K | -306K | -421K | -265.32K | -7.41M | -51.27K | -172.73K | -170.91K | -115.02K |
Financing activities | ||||||||||
Common Stock Issued | 5M | 100M | 75M | 50M | 37.82M | 21.13M | 37.17M | 2.29M | 31.65K | 9.11M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -24.68M | 520M | -110M | 0 | 0 | -181.17K | 0 | 0 | 0 | -84.67K |
Cash used in financing activities | 86.51M | 620.24M | 77.91M | 50.55M | 37.46M | 19.68M | 22.13M | 2.13M | 25.32K | 8.13M |
Net Change In Cash | -577.18M | 576.81M | 5.37M | 2.57M | 27.69M | -11.26M | 7.17M | -1.84M | -4.48M | 5.37M |
Cash at end of period | 71.42M | 648.60M | 71.79M | 66.41M | 49.96M | 28.45M | 23.22M | 3.25M | 5.14M | 9.71M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |